Sign Up
OverviewAPI
Waldencast plc (NASDAQ: WALD) confronts accounting irregularities post its Obagi Skincare acquisition, causing CFO departure and SEC scrutiny. Overstated revenues lead to share price decline and suspicions of intentional financial misrepresentation.

Ask a question